ATAI

#2139
AtaiBeckley Inc. Common Stock
4.3300 USD
-0.23%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
4.3300
4.3300
년간 변동
3.2700
5.5000
일일 변동
-0.23%
월간 변동
+28.49%
6달 변화
+9.62%
년간 변동율
+9.62%
이전 종가
4.3400
시가
4.3300
저가
4.3300
High
4.3300
양
64
전체 차트 열기

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 1.5794 B
  • Employee 99
  • Founded 2018
  • CEO Florian Brand
  • Website www.ataibeckley.com
  • Headquarter Delaware, United States
  • FIGI BBG0107FR3K9
  • Industry 생명공학
총매출
순이익
총부채
잉여 현금 흐름
현금 및 현금성 자산

AtaiBeckley Inc

atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways.

뉴스